GLPwatch
Papers (10401)
Page 61 of 174, ranked by citation count.
- Exendin-4 Prevents Memory Loss and Neuronal Death in Rats with Sporadic Alzheimer-Like Disease.
- Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.
- Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
- Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.
- Semaglutide for the Treatment of Type 2 Diabetes Mellitus.
- Effects of incretin-based therapy in patients with heart failure and myocardial infarction.
- Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.
- Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.
- Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
- B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells.
- GLP-1 agonist Liraglutide prevents MK‑801-induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice.
- Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists.
- Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.
- Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.
- Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system.
- Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.
- Liraglutide-Loaded Milk Exosomes Lower Blood Glucose When Given by Sublingual Route.
- Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.
- The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery.
- Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
- <i>GLP1R</i> Single-Nucleotide Polymorphisms rs3765467 and rs10305492 Affect β Cell Insulin Secretory Capacity and Apoptosis Through GLP-1.
- Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
- Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
- Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
- Future directions in obesity pharmacotherapy.
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
- Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.
- Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease.
- Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
- Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.
- Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System.
- The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
- Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.
- Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
- Validation studies on blood collection from the jugular vein of conscious mice.
- Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.
- The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
- Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate.
- Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users.
- A case report: Liraglutide as a novel treatment option in late dumping syndrome.
- Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
- Case Series: Exposure to Glucagon-like Peptide-1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings.
- Advances in GLP-1 treatment: focus on oral semaglutide.
- A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model.
- Peptide GLP-1 receptor agonists: From injection to oral delivery strategies.
- Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
- Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.
- Comparative studies on exenatide-loaded poly (D,L-lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying.
- GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.
- Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.
- Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
- Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.
- Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.
- Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
- Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.
- Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.